Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes

被引:708
作者
Munn, DH
Sharma, MD
Hou, D
Baban, B
Lee, JR
Antonia, SJ
Messina, JL
Chandler, P
Koni, PA
Mellor, AL
机构
[1] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA
[2] Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA
[3] Med Coll Georgia, Dept Pathol, Augusta, GA 30912 USA
[4] Vet Affairs Med Ctr, Augusta, GA USA
[5] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[6] Med Coll Georgia, Dept Med, Augusta, GA 30912 USA
关键词
D O I
10.1172/JCI200421583
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO). Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs. Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs. Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice. Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19. We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.
引用
收藏
页码:280 / 290
页数:11
相关论文
共 82 条
[1]   Role of indoleamine-2,3-dioxygenase in alpha/beta and gamma interferon-mediated antiviral effects against herpes simplex virus infections [J].
Adams, O ;
Besken, K ;
Oberdörfer, C ;
MacKenzie, CR ;
Takikawa, O ;
Däubener, W .
JOURNAL OF VIROLOGY, 2004, 78 (05) :2632-2636
[2]  
Almand B, 2000, CLIN CANCER RES, V6, P1755
[3]   Mouse type IIFN-producing cells are immature APCs with plasmacytoid morphology [J].
Asselin-Paturel, C ;
Boonstra, A ;
Dalod, M ;
Durand, I ;
Yessaad, N ;
Dezutter-Dambuyant, C ;
Vicari, A ;
O'Garra, A ;
Biron, C ;
Brière, F ;
Trinchieri, G .
NATURE IMMUNOLOGY, 2001, 2 (12) :1144-1150
[4]  
Björck P, 1998, J IMMUNOL, V161, P5795
[5]  
Bodaghi B, 1999, J IMMUNOL, V162, P957
[6]   A universal granulocyte-macrophage colony-stimulating factor-producing bystander cell line for use in the formulation of autologous tumor cell-based vaccines [J].
Borrello, I ;
Sotomayor, EM ;
Cooke, S ;
Levitsky, HI .
HUMAN GENE THERAPY, 1999, 10 (12) :1983-1991
[7]  
Bronte V, 1999, J IMMUNOL, V162, P5728
[8]  
BUBNOFF D, 2002, J IMMUNOL, V169, P1810
[9]   The lymphoid past of mouse plasmacytoid cells and thymic dendritic cells [J].
Corcoran, L ;
Ferrero, I ;
Vremec, D ;
Lucas, K ;
Waithman, J ;
O'Keeffe, M ;
Wu, L ;
Wilson, A ;
Shortman, K .
JOURNAL OF IMMUNOLOGY, 2003, 170 (10) :4926-4932
[10]  
Cuenca A, 2003, CANCER RES, V63, P9007